🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 207127 NA

Found 9 matching trials

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

PHASE1

The purpose of this study was to investigate antiviral activity, safety and...

Status

Completed

Location

Multiple Locations

Start Date

2007-12

Trial ID

NCT02176525

Treatments Being Tested

BI 207127 NA Placebo

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

PHASE1

Phase 1 study to assess the pharmacokinetics and routes of elimination of a...

Status

Completed

Location

1241.22.001 Boehringer Ingelheim Investigational Site

Start Date

2012-05

Trial ID

NCT01605461

Treatments Being Tested

BI 207127 NA

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

PHASE1

Study to investigate the relative bioavailability of 5 new 400 mg tablet fo...

Status

Completed

Location

Multiple Locations

Start Date

2009-05

Trial ID

NCT02182414

Treatments Being Tested

BI 207127 NA (TF-I)BI 207127 NA (TF-II)BI 207127 NA delayed release BI 207127 NA extended release (10% HPMC)BI 207127 NA extended release (15% PEO)BI 207127 NA extended release (20% HPMC)

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

PHASE1

Study to investigate the pharmacokinetic drug-drug interaction potential of...

Status

Terminated

Location

Multiple Locations

Start Date

2009-07

Trial ID

NCT02182401

Treatments Being Tested

BI 207127 NA BI 201335 NA Midazolam Tolbutamide

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

PHASE1

The primary objective of the current study is to investigate the relative b...

Status

Completed

Location

1241.26.1 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01535638

Treatments Being Tested

BI 207127 BI 207127 BI 207127

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

PHASE1

The objective of this trial was to investigate the safety, tolerability, ph...

Status

Completed

Location

Multiple Locations

Start Date

2007-01

Trial ID

NCT02182388

Treatments Being Tested

Placebo BI 207127 NA powder for solution BI 207127 NA tablet

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

PHASE1

The aim of the study is to evaluate safety, tolerability and pharmacokineti...

Status

Completed

Location

1241.8.8201 Boehringer Ingelheim Investigational Site

Start Date

2011-05

Trial ID

NCT01347086

Treatments Being Tested

Matching placebo (low dose)BI 207127 NA (medium dose)BI 207127 NA (low dose)Matching placebo (medium dose)BI 207127 NA (high dose)Matching placebo (high dose)

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

PHASE1

The main purpose of this clinical trial with BI 207127 is to see the effect...

Status

Completed

Location

1241.7.3307A CHU de Grenoble

Start Date

2009-05

Trial ID

NCT00905632

Treatments Being Tested

BI 207127 middle dose +SOC BI 207127 high dose+SOC Placebo + SOC BI 207127 low dose + SOC

Previous Next